ISV Asia Meeting Overview
The International Society for Vaccines (ISV) was established in 1992 when several scientists working in the field of vaccines suggested that a professional and academic society should be developed and devoted to all aspects of vaccines. Nearly three decades later ISV has become one of the worlds most recognizable non-for profit organizations in the global vaccine community. While ISV has grown over the years, its overall ambition remains unchanged: to encourage, establish and promote the development and the use of vaccines to prevent and control infectious and non-infectious diseases in humans and animals.
ISV engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines. ISV provides exclusive membership benefits to those actively engaged in promoting the aims and objectives of the society. ISV hosts an annual Congress in October every year, which serves as the worlds largest non-for profit scientific conference related to vaccines and covers a broad range of topics related to vaccinations and immunotherapies. The ISV Congress brings together individuals from all sectors of the global vaccine community to hear about the latest advances in the field, discuss challenges and opportunities, and network.
ISV engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines. ISV provides exclusive membership benefits to those actively engaged in promoting the aims and objectives of the society. ISV hosts an annual Congress in October every year, which serves as the worlds largest non-for profit scientific conference related to vaccines and covers a broad range of topics related to vaccinations and immunotherapies. The ISV Congress brings together individuals from all sectors of the global vaccine community to hear about the latest advances in the field, discuss challenges and opportunities, and network.
ISV Asia Meeting Program
Date : Nov. 16(Fri)
Time | Contents | Speaker |
---|---|---|
08:00 ~ 08:05 | Opening remarks | Joon Haeng Rhee |
08:05 ~ 09:20 | Viral vaccines | |
08:05 ~ 08:20 | Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein | Linqi Zhang |
08:20 ~ 08:35 | Immunogenic study of an enterovirus type 71 and coxsackievirus A 16 inactivated vaccine based on mechanistic analysis of activated innate lymphoid cells and dendritic cells | Qihan Li |
08:35 ~ 08:50 | Development of a broadly protective vaccine against hand, foot, and mouth disease | Zhong Huang |
08:50 ~ 09:05 | Dengue NS1: a Key Factor for Virus Transfer from Host to Mosquito Vector | Gong Cheng |
09:05 ~ 09:20 | Efficacy and safety of an E. coli-produced human papillomavirus vaccine (types 16 and 18) | Jun Zhang |
09:30 ~ 10:00 | Plenary Lecture | |
09:30 ~ 10:00 | Iterative optimization by structure-based vaccine design | Peter Kwong |
10:05 ~ 11:25 | Adjuvant and Delivery I | |
10:05 ~ 10:25 | The Adjuvant Database for preclinical evaluation of vaccines and immunotherapy agents | Ken Ishii |
10:25 ~ 10:40 | Immunological mechanism of synergistic anti-cancer activities by activation of TLR9 and STING | Burcu Temizoz |
10:40 ~ 10:55 | Intrinsic MyD88 signalling in B cells controls IFNγ-mediated early IgG2c class switching in response to a particulate adjuvant | Michelle S.J. Lee |
10:55 ~ 11:10 | The mode of action by which hydroxypropyl-β-cyclodexrin (HP-β-CD) functions as a vaccine adjuvant | Takato Kusakabe |
11:10 ~ 11:25 | A built-in adjuvant-engineered mucosal vaccine against dysbiotic periodontal diseases | Shee Eun Lee |
11:35 ~ 12:35 | Influenza Vaccine I | |
11:35 ~ 11:50 | Rational design of site-specific glycan-masking and glycan-unmasking HA antigens for influenza vaccines | Suh-chin Wu |
11:50 ~ 12:05 | Modifying hemagglutinin glycosylation in candidate vaccine virus shows the cross-reactivity against influenza viruses | Manseong Park |
12:05 ~ 12:20 | Advancing Cross-protection of Influenza Vaccines by Virus-Like Particle Technology | Pei-Wen Hsiao |
12:20 ~ 12:35 | A Replicating Adenovirus-Influenza H5 Vaccine Induces Prolonged Evolution of the Memory B Cell Response | Jinghe Huang |
12:35 ~ 13:30 | Lunch (55') | |
13:30 ~ 14:30 | Bacterial Vaccines | |
13:30 ~ 13:45 | Injection route is an important factor for immunization of D-Ala and D-Glu auxotrophic Staphylococcus aureus mutants in the murine model | Bok Leul Lee |
13:45 ~ 14:00 | Development of scrub typhus vaccine providing broad genotype protection | Nam-Hyuk Cho |
14:00 ~ 14:15 | Effective prime-boost immunization against tuberculosis with heterologous viral vectors | Hye Sook Jeong |
14:15 ~ 14:30 | Use of High-Energy Radiation to Develop Efficient Inactivated and Attenuated Vaccines | Ho Seong Seo |
14:40 ~ 15:00 | Vaccine Science | |
14:40 ~ 15:00 | Antigen specific Treg cell is a gatekeeper against anti-viral and anti-tumor responses—thinking ahead for vaccine design | Bin Wang |
15:00 ~ 15:15 | Comparative analysis of whole-organ and organism-specific adjuvant transcriptomes in a systems vaccinology approach | Lokesh P. Tripathi |
15:15 ~ 15:30 | PD1-based Vaccine Potentiates Host Immunity for HIV-1 Functional Cure | Zhiwei Chen |
15:30 ~ 15:45 | Research Progress on Chinese Therapeutic Hypertensive Vaccine | Yu-Hua Liao |
15:55 ~ 17:10 | Adjuvant and Delivery II | |
15:55 ~ 16:10 | Necroptoic cell death governs neutrophil-mediated inflammation in influenza virus infection via IL-1 alpha | Masatoshi Momota |
16:10 ~ 16:25 | Enhanced protective effect of influenza split vaccination by the combination of DAMP-inducing and PAMP adjuvants | Tomoya Hayashi |
16:25 ~ 16:40 | Molecular interaction between IL-1 alpha and genomic DNA released by Alum-induced cell death | Kou Hioki |
16:40 ~ 16:55 | Material-based High-performance Vaccines Potentiate Antitumor Therapy | Wei Wei |
16:55 ~ 17:10 | Improved intradermal vaccination using coated microneedle | Yeu-Chun Kim |
17:10 ~ 18:20 | Influenza Vaccine II | |
17:20 ~ 17:35 | Influenza vaccine and antibody dependent cellular cytotoxicity | Che Alex Ma |
17:35 ~ 17:50 | A monoclonal antibody-based immunoassay for measuring the potency of seasonal flu vaccines | Juine Ruey Chen |
17:50 ~ 18:05 | Protective immune responses during H7N9 infection and vaccine development | Jianqing Xu |
18:05 ~ 18:20 | Towards Universal Influenza Vaccine: Pan-influenza A Protection by X-31 Cold-adapted Live Attenuated Vaccine | Baik Lin Seong |
* The program is subject to change.